Arrowhead Pharmaceuticals, Inc. ARWR
59.53 USD -0.04 (-0.07%)
At closeNov 3, 2026, 4:01 PM EST
59.53 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
59.25 Day range 60.89
37.06 52-week range 95.49
- YTD
- -10.33%
- 1 year
- +50.29%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 107.71 +80.9% upside
Now 59.53
- Target (low)
- 74.00
- Target (mean)
- 107.71
- Target (high)
- 126.00
Ratings (0m) 15 14 buy · 1 hold · 0 sell
- Strong buy4
- Buy10
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 15
- 1 month ago 14
- 2 months ago 12
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.50 | -3.00 – -0.34527 | -0.18 | -735.1% | 60.44M | -76.4% | 15 |
| Next quarter | -1.37 | -1.75 – -1.00 | 0.22 | -721.0% | 45.76M | -82.7% | 7 |
| Current year | -3.51 | -5.14 – -2.45 | -0.01 | -35034.2% | 464.14M | -44.0% | 15 |
| Next year | -4.98 | -6.58 – -2.66 | -3.51 | -41.7% | 328.22M | -29.3% | 15 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2026 | Citigroup | Initiated | — | Buy |
| Sep 1, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 31, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Aug 31, 2026 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 30, 2026 | B. Riley Securities | Maintained | Buy | Buy |
| Jul 27, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 23, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jul 22, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jul 17, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 14, 2026 | Stifel | Initiated | — | Buy |
| Jul 1, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 30, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Jun 17, 2026 | Leerink Partners | Maintained | Market Perform | Market Perform |
| May 13, 2026 | Bernstein | Maintained | Market Perform | Market Perform |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 1, 2026 | JP Morgan | Initiated | — | Overweight |
| Apr 21, 2026 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| Mar 25, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 22, 2026 | B. Riley Securities | Maintained | Buy | Buy |
| Jan 21, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jan 13, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Jan 7, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Jan 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jan 7, 2026 | Chardan Capital | Maintained | Buy | Buy |
| Dec 17, 2025 | Piper Sandler | Maintained | Overweight | Overweight |